Iroko Pharmaceuticals Release: ZORVOLEX™ (diclofenac) Utilizing SoluMatrix Fine Particle Technology™ Was Well-Tolerated in Treatment of Osteoarthritis Pain

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today presented Phase 3 results from a study of ZORVOLEX™ (diclofenac) capsules in patients with osteoarthritis pain. Taken over a period of twelve weeks, there were no ZORVOLEX™- related serious gastrointestinal, renal or cardiovascular (myocardial infarction or stroke) adverse events1, which are all risks associated with nonsteroidal anti-inflammatory drugs (NSAIDs). 2,3,4,5 These data were presented at the 2013 American College of Rheumatology (ACR) Annual Scientific Meeting in San Diego. ZORVOLEX is now approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate acute pain in adults and is under investigation for the treatment of osteoarthritis pain.

Help employers find you! Check out all the jobs and post your resume.

Back to news